Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean biotech Celltrion plans on speeding up development of its biosimilars by selling a 10 percent stake in the company to Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings

You may also be interested in...



Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business

Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval shortly in Europe for a biosimilar of J&J’s Remicade.

Singapore's Ion Investments Buys Another 10% Stake In Korea's Celltrion In Anticipation of 2012 Biosimilars Launch

SEOUL - Celltrion, Inc. said Sept. 1 that Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings Pte. Ltd., purchased 10% of the outstanding shares of Celltrion Healthcare Co., Celltrion's global distribution and marketing arm, increasing the investor's share in the Korean company

Singapore's Ion Investments Buys Another 10% Stake In Korea's Celltrion In Anticipation of 2012 Biosimilars Launch

SEOUL - Celltrion, Inc. said Sept. 1 that Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings Pte. Ltd., purchased 10% of the outstanding shares of Celltrion Healthcare Co., Celltrion's global distribution and marketing arm, increasing the investor's share in the Korean company

Related Content

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel